Latest Conference Articles

Alan Blassberg, Director/Producer of Pink and Blue: Colors of Hereditary Cancer, discusses being a male BRCA carrier.

Sharon Bober on Asking Your Doctor About Sexual Health

June 10th 2017, 8:09pm

Sharon Bober, PhD, discusses how patients can ask their doctors about sexual health.

Understanding Mastectomy and Reconstruction Options Can Ease Difficult Decisions

June 10th 2017, 5:56pm

Those considering mastectomy to help prevent inherited breast cancer, or because they’ve been diagnosed with the disease, are likely to find themselves sorting through a host of complex questions.

Less Invasive Techniques Gaining Traction in Ovarian Cancer Prevention

June 10th 2017, 4:22pm

For women genetically predisposed to ovarian cancer, prevention is extremely important. But what are the most effective and least invasive prevention techniques, and when is the best time in life to employ them?

All in the Family: The Importance of Talking About Hereditary Cancer

June 9th 2017, 11:58pm

Knowing that you have an inherited gene mutation can allow you and your family members to look into prevention or detect a cancer at an early stage.

Angela Fishbaugh on Discovering Your Story and Skills

June 9th 2017, 11:15pm

Angela Fishbaugh, author of "Angela's Decision," discusses how to discover your skills and story within.

Extending Progression-Free Survival in BRCA-Positive Breast Cancer

June 9th 2017, 11:02pm

“This is the first phase 3 study to show an advantage of a PARP inhibitor over standard of care chemotherapy in breast cancer patients with a BRCA mutation,” said principal OLYMPIAD investigator Mark E. Robson, M.D., Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center.

Ilana Cass on Potential Consequences of Preventive Surgery

June 9th 2017, 10:32pm

Ilana Cass, M.D. of Cedars-Sinai Medical Center discusses some of the unknown potential side effects of preventive surgery for ovarian cancer.

Being a 'FORCE' In Hereditary Cancers for 18 Years: An Interview with Executive Director Sue Friedman

June 9th 2017, 8:48pm

Sue Friedman, executive director and founder of FORCE, is a hereditary breast cancer survivor herself and has been concentrating on being the support system for others that she didn’t have when she was going through her battle 20 years ago.

XRAYS Separates the Help from the Hype to Make Sense of Cancer Research in the News

June 9th 2017, 8:03pm

The program XRAYS is a resource to help patients, survivors and their loved ones make sense of the articles on hereditary cancer they see in the mainstream media and via social media platforms.

Ethical Dilemmas Arise from Genetic Testing for Cancer

June 9th 2017, 5:21pm

While genetic testing for cancer has some obvious benefits, it also creates ethical dilemmas in many cases.

Nail Bed Balm Proves Successful in Preventing Chemotherapy-Related Nail Damage

June 8th 2017, 6:28pm

PolyBalm was effective in mitigating chemotherapy-related nail damage, according to a recent study presented at ASCO.

Promising Combination Moves Into Kidney Cancer

June 7th 2017, 5:44pm

Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.

Drug Combination Is Effective in Urothelial Carcinoma

June 6th 2017, 10:06pm

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.

Therapy Shows High Remission Rates in Multiple Myeloma

June 6th 2017, 5:59pm

Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.

Will There Be an Immunotherapy Approval in Gastric Cancer?

June 5th 2017, 9:55pm

Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.

New Agent Shows Promise Across Many Cancers Which Have TRK Fusion Mutations

June 5th 2017, 6:48pm

Promising results from a new agent may set the stage for a new standard of care for patients with TRK fusion mutations.

With Patients Reporting Symptoms Using Web Tool, Survival Improves

June 4th 2017, 10:21pm

An online tool helped patients to report their symptoms in real time, improving survival, according to findings presented at ASCO 2017.

Patients With Low-Risk Colon Cancer Can Have Less Chemotherapy, Reducing Neuropathy

June 4th 2017, 10:06pm

According to findings presented at ASCO 2017, patients with low-risk advanced colon cancer would benefit from reducing the length of chemotherapy after surgery.

Staying CALM: Psychotherapy for Patients with Advanced Cancers

June 4th 2017, 8:19pm

The psychotherapty known as CALM has been shown to ease depression and distress in patients with advanced cancer.

Maintaining Mobility May Not Require More Than Single-Dose Radiation

June 4th 2017, 5:59pm

According to phase III findings presented at ASCO 2017, single radiation treatment relieved the symptoms of spinal cord compression in patients with advanced cancer as effectively as a five-day course.

Study Finds a Decline in Late Effects After Childhood Treatment

June 3rd 2017, 8:38pm

There are fewer reported incidences of severe long-term side effects after childhood cancer treatment, according to a recent study.

Psychological Interventions Can Lower Fear of Recurrence

June 2nd 2017, 11:47pm

A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.

Combination Improves Breast Cancer Survival, Study Shows

June 2nd 2017, 11:07pm

Progression-free survival was improved for postmenopausal women with HER2-negative advanced breast cancer when treated with Kisqali plus letrozole.

Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer

March 15th 2017, 9:19pm

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improving Survival in BRCA-Proficient Ovarian Cancer

March 15th 2017, 8:20pm

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer

March 15th 2017, 6:41pm

Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer

March 15th 2017, 4:52pm

PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

March 15th 2017, 12:37am

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Niraparib Improves Progression-Free Survival in Ovarian Cancer, Regardless of BRCA Status

March 14th 2017, 10:32pm